{"organizations": [], "uuid": "176be5e391c817da9992972c4ec604ca74516e63", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-catalyst-biosciences-announces-pos/brief-catalyst-biosciences-announces-positive-top-line-data-from-phase-1-2-study-of-subcutaneous-cb-2679d-isu304-idUSFWN1PZ0YR", "country": "US", "domain_rank": 408, "title": "BRIEF-Catalyst Biosciences Announces Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous Cb 2679D/Isu304", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-09T14:57:00.000+02:00", "replies_count": 0, "uuid": "176be5e391c817da9992972c4ec604ca74516e63"}, "author": "", "url": "https://www.reuters.com/article/brief-catalyst-biosciences-announces-pos/brief-catalyst-biosciences-announces-positive-top-line-data-from-phase-1-2-study-of-subcutaneous-cb-2679d-isu304-idUSFWN1PZ0YR", "ord_in_thread": 0, "title": "BRIEF-Catalyst Biosciences Announces Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous Cb 2679D/Isu304", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-catalyst biosciences announces positive t", "sentiment": "negative"}, {"name": "study of subcutaneous cb 2679d/isu304 reuters", "sentiment": "none"}, {"name": "catalyst biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 9, 2018 / 12:57 PM / Updated 16 minutes ago BRIEF-Catalyst Biosciences Announces Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous Cb 2679D/Isu304 Reuters Staff 1 Min Read \nFeb 9 (Reuters) - Catalyst Biosciences Inc: \n* CATALYST BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 1/2 STUDY OF SUBCUTANEOUS CB 2679D/ISU304 IN INDIVIDUALS WITH HEMOPHILIA B \n* CATALYST BIOSCIENCES INC - ALL INDIVIDUALS WITH SEVERE HEMOPHILIA IMPROVED TO MILD HEMOPHILIA ACTIVITY LEVELS AFTER ONLY SIX DAILY DOSES \n* CATALYST BIOSCIENCES - ‍RESULTS SUGGEST LONG-TERM DOSING OF SQ CB 2679D COULD MAINTAIN STABLE CLOTTING ACTIVITY IN HIGH-MILD HEMOPHILIA TO NORMAL RANGE​ \n* CATALYST BIOSCIENCES INC - ‍NO INHIBITORS TO CB 2679D OR FIX WERE INDUCED TO DATE​ \n* CATALYST BIOSCIENCES-‍1 SUBJECT HAD MODERATE ADVERSE EVENTS OF PAIN,ERYTHEMA,REDNESS AFTER FIRST 2 INJECTIONS, MILD RATING AFTER SUBSEQUENT INJECTIONS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-09T14:57:00.000+02:00", "crawled": "2018-02-09T15:20:31.000+02:00", "highlightTitle": ""}